The inhibition of BDK, the enzyme responsible for phosphorylating and inactivating BCKD, or the overexpression of protein phosphatase-1K (PPM1K), which dephosphorylates and activates BCKD, has been reported to reduce circulating BCAA levels, alleviate hepatic steatosis, and improve glucose tolerance [53]. Here, BCKDK is linked to fatty liver disease.